Effects of corilagin on alleviating cholestasis via farnesoid X receptor-associated pathways in vitro and in vivo.

作者: Fan Yang , Yao Wang , Gang Li , Juan Xue , Zhi-Lin Chen

DOI: 10.1111/BPH.14126

关键词:

摘要: BACKGROUND AND PURPOSE The aim of this study was to investigate the ameliorative effects corilagin on intrahepatic cholestasis induced by regulating liver farnesoid X receptor (FXR)-associated pathways in vitro and vivo. EXPERIMENTAL APPROACH Cellular animal models were treated with different concentrations corilagin. In cellular experiments, FXR expression up-regulated either lentiviral transduction or GW4064 treatment down-regulated siRNA technology guggulsterones. Real-time PCR Western blotting employed detect mRNA protein levels FXR, SHP1, SHP2, UGT2B4, BSEP, CYP7A1, CYP7B1, NTCP, MRP2 SULT2A1. Immunohistochemistry used examine BSEP tissues. Rat function pathological changes hepatic tissue assessed using biochemical tests haematoxylin eosin staining. RESULTS Corilagin increased SULT2A1, decreased those CYP7B1 NTCP. After up- down-regulating methods, could still increase SULT2A1 decrease especially when administered at a high concentration. also exerted notable effect manifestations cholestasis, staining tissues function. CONCLUSIONS IMPLICATIONS exerts protective hepatocytes can prevent deleterious activities stimulating FXR-associated pathways.

参考文章(58)
Valentina Sepe, Eleonora Distrutti, Stefano Fiorucci, Angela Zampella, Farnesoid X receptor modulators (2011 - 2014): a patent review. Expert Opinion on Therapeutic Patents. ,vol. 25, pp. 885- 896 ,(2015) , 10.1517/13543776.2015.1045413
Feng Jin, Ran Zhang, Song Feng, Chuan-Tao Yuan, Ren-Ya Zhang, Guang-Kui Han, Gen-Hua Li, Xi-Zhen Yu, Yang Liu, Ling-Sheng Kong, Shu-Ling Zhang, Lei Zhao, Pathological features of transplanted tumor established by CD133 positive TJ905 glioblastoma stem-like cells Cancer Cell International. ,vol. 15, pp. 60- 60 ,(2015) , 10.1186/S12935-015-0208-Y
Carol Kilkenny, William Browne, Innes C Cuthill, Michael Emerson, Douglas G Altman, None, Animal research: reporting in vivo experiments: the ARRIVE guidelines British Journal of Pharmacology. ,vol. 160, pp. 1577- 1579 ,(2010) , 10.1111/J.1476-5381.2010.00872.X
Michael J Curtis, Richard A Bond, Domenico Spina, Amrita Ahluwalia, Stephen P A Alexander, Mark A Giembycz, Annette Gilchrist, Daniel Hoyer, Paul A Insel, Angelo A Izzo, Andrew J Lawrence, David J MacEwan, Lawrence D F Moon, Sue Wonnacott, Arthur H Weston, John C McGrath, Experimental design and analysis and their reporting: new guidance for publication in BJP. British Journal of Pharmacology. ,vol. 172, pp. 3461- 3471 ,(2015) , 10.1111/BPH.12856
Frank J. Gonzalez, Nuclear receptor control of enterohepatic circulation. Comprehensive Physiology. ,vol. 2, pp. 2811- 2828 ,(2012) , 10.1002/CPHY.C120007
John C McGrath, Elliot Lilley, Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP British Journal of Pharmacology. ,vol. 172, pp. 3189- 3193 ,(2015) , 10.1111/BPH.12955
Yan Ding, Lei Zhao, Hong Mei, Shu-Ling Zhang, Zhi-Hua Huang, Yan-Ying Duan, Pian Ye, Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway European Journal of Pharmacology. ,vol. 590, pp. 377- 386 ,(2008) , 10.1016/J.EJPHAR.2008.06.044
Mitsuhiro Watanabe, Sander M. Houten, Li Wang, Antonio Moschetta, David J. Mangelsdorf, Richard A. Heyman, David D. Moore, Johan Auwerx, Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation. ,vol. 113, pp. 1408- 1418 ,(2004) , 10.1172/JCI21025
Sayeepriyadarshini Anakk, Mitsuhiro Watanabe, Scott A. Ochsner, Neil J. McKenna, Milton J. Finegold, David D. Moore, Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis. Journal of Clinical Investigation. ,vol. 121, pp. 86- 95 ,(2011) , 10.1172/JCI42846